Under 10% of individuals who could benefit from GLP-1 drugs like Wegovy have access to them, warns the World Health Organization as it issues its initial recommendations on the medications.
With in excess of 1,000,000,000 people worldwide currently obese, it is urging broader and more equitable access to these injectable treatments.
Based on estimates, more than two billion could be obese by 2030 without intervention.
"Our latest guidelines acknowledges that obesity is a long-term condition that can be addressed with comprehensive and lifelong support," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and supply-chain constraints are significant obstacles to broad availability to the jabs that can assist patients in reducing considerable body mass, explains the organization.
Weight-Loss Drug Scarcity
Even in the current best projected case, the supply of these medications could only cover about 100 million people – under 10% of the global need, according to the health organization.
The advice encourages governments and firms to expand access, through measures like licensing agreements.
Exclusive production rights on the active ingredient – the main ingredient of the drug Wegovy – is scheduled to end in a number of nations in 2026.
How Weight-Loss Drugs Operate
The injections replicate a biological compound to slow digestion, reduce hunger and increase the sense of being full so individuals eat less.
Patients usually see weight reduction after several weeks of commencing the regular doses.
Research indicates people may regain a significant portion after a year of discontinuing the medication, because their normal appetite come back.
To be above a healthy weight increases your chance for developing diseases, including type 2 diabetes, cardiovascular issues, brain attack, and certain cancers.
Excess weight impacts people in all nations and was linked to millions of fatalities worldwide in 2024, per the health agency.
